Ipca Labs Receives 'Add' Rating from Dolat Capital Post Q4 Results
Dolat Capital has maintained an 'Add' rating on Ipca Laboratories Limited following its Q4 results. The brokerage firm highlights multiple growth drivers including cost efficiencies, Unichem portfolio scale-up, and US market expansion plans. Ipca Labs aims to launch 12-13 new products in the US over the next two years, signaling a strong commitment to portfolio diversification and market share growth in this key pharmaceutical market.
29May 25
IPCA Laboratories: Q4 Profit Rises 14%, but Full-Year EBITDA Margin Falls Short of Guidance
IPCA Laboratories reported a 14% YoY increase in Q4 net profit to ₹68.00 crore, with revenue up 11% to ₹2,247.00 crore. Q4 EBITDA grew 33%. However, full-year EBITDA margin at 19.00% missed the company's 23-24% guidance. A final dividend of ₹2.00 per share was announced.
28Mar 25
IPCA Laboratories to Sell Tarapur Facility and Acquire Unichem Ireland in Strategic Moves
IPCA Laboratories is selling its Tarapur manufacturing facility for 36.90 crore rupees to optimize operations and reduce costs. Simultaneously, the company is acquiring Unichem Laboratories' Irish subsidiary for 4 crore rupees to establish a presence in the European market. The Tarapur sale is expected to complete by June 30, 2025, while the Irish acquisition will be renamed Ipca Laboratories (Europe) Ltd. These strategic moves aim to streamline manufacturing and expand international presence.